Prediction time. Here’s what I think will happen in the coming months. Just to clarify, (a) this is based on complete guesswork, and (b) I am an awful prognosticator. I’d suggest doing the opposite, like the Seinfeld episode. But I’ll give it a whirl anyway. First, we will see Q3 shortly. Among other things, it will announce the filing of Form 10 in October. We will resume trading sometime in December. There will be a rapid sell-off in the early days, which will present a final buying opportunity as a penny stock. Market makers and folks like me will gladly absorb the shares, keeping the price between .25 and.50. After this initial reshuffling of ownership, the combination of news and strong demand in at least two key sectors (the DVCStem business and Infinivive), in conjunction with the media activity of a more aggressive CEO, will begin to drive interest in the stock. I expect it to see $2 - $3 by Q2 of CY22. From there, FDA-related news will either push the stock into the $6-$7 range or cause it to fall to a dollar or so temporarily before gradually recovering. If FDA news is positive, and if we finally see some real news from the Patent office, then I would expect that the M&A rumor mill will begin to churn, potentially driving the share price to $10 later in the year. If there is no news on the FDA or IP fronts, but revenues continue to look good, then I’d expect the stock to be at $4-$5 by the end of CY22, with the quarterlies becoming a factor in price volatility. The market capitalization at that point will be in the $200+ million range. That doesn’t mean the company is really worth that much, but I believe this is how the market will value a small biotech like this that has survived for decades and is now executing both in the market and in the domestic regulatory realm.
Obviously, this all speculation and storytelling for the fun of it. It is just as possible that they drag their feet, we’re still not trading in January, and, when it does resume, market capitalization remains south of $10 million based on P&L fundamentals and continued general skepticism toward stem cell technologies and the charlatans who promote it irresponsibly. But I see that as less likely at this point, simply because I think the brands and revenues alone will demand a share price over a buck as we get into 2022. Whether that can morph into full recognition as a legit player in the biotech space, and the type of performance I alluded to earlier, is an interesting question. We should have the answers in the coming months though. Finally.
